EndoRx LLC is pleased to announce that CONMED Inc. has executed an agreement to acquire the rights to the Rhino biliary stone balloon product line. The purchase price and terms of the agreement are confidential.
The Rhino is a balloon catheter system used for stone retrieval, occlusion of the duct, and contrast injection during ERCP procedures in the biliary system. The Rhino is the first device of its kind designed with progressive balloon expansion capabilities from 9-22mm, allowing physicians to customize the balloon size to the exact diameter of each patient’s duct. In addition to the unique balloon design, the Rhino is the first quad lumen stone retrieval device combining both above and below contrast port capabilities.
“We are honored to see the Rhino line assimilated into the expanding portfolio of advanced therapeutic products in the CONMED Endoscopic Technology Division,” says Endo-Rx CEO Christen Springs.
“CONMED has a long-standing reputation for innovation and customer service. We look forward to seeing the success of the technology grow under their leadership.”
EndoRx co-Founder Dr. Isaac Raijman adds, “We are proud to see The Rhino balloon expand in the market through CONMED. The Rhino balloon represents the unmet needs faced by endoscopists during ERCP procedures for stone extraction. The expanded capabilities and durability of this product will prove invaluable to endoscopists.”
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. Its products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardia monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,400 employees distribute its products worldwide from several manufacturing locations.
Houston based EndoRx LLC was formed in 2011 with the goal of bringing innovative technologies to market in the advanced endoscopy space. The Rhino device received 510K FDA clearance in the summer of 2014 and was formally launched at the Digestive Disease Week Conference in May 2015. At the time of acquisition, EndoRx owned one issued patent with two additional patents pending on the designs of the Rhino. EndoRx maintains a healthy development portfolio of devices for advanced endoscopy and will continue to innovate and develop disruptive technologies in the gastrointestinal space.
Christen Springs joined EndoRx in 2015 serving as CEO and General Manager. Mr. Springs oversees all EndoRx operations including management of sales and marketing, regulatory, vendor relations, and product management. Mr. Springs has 17 years of medical device experience in sales, marketing, product development, and sales management. Prior to joining EndoRx, Mr. Springs managed the launch of 3 medical device technologies resulting in over 40 million in US revenue. He holds a BBA in Finance from Texas A&M University and is co-inventor of 5 medical device patents and patents pending.
Dr. Isaac Raijman is a founder of EndoRx and serves as Chief Medical Officer. Dr. Raijman graduated from medical school in Mexico. After completing his residency at the Medical College of Wisconsin, he finished a gastroenterology fellowship at the University of Texas Medical School at Houston.
Dr. Raijman then completed a therapeutic endoscopy fellowship at the Wellesley Hospital in Toronto, Canada. He has served multiple clinical positions since his return to Houston in 1993 and is currently the Chief of Gastroenterology at CHI Baylor St. Luke’s hospital, clinical associate professor at Baylor College of Medicine and clinical associate professor at the University of Texas Medical School at Houston. In addition, Dr. Raijman is the owner of Digestive Associates of Houston. Dr. Raijman created the original concept of the Rhino, and, in his role as CMO, is responsible for creating new product concepts and clinical evaluation and development of the EndoRx portfolio.